- Home
- ACRS vs COOK Comparison
ACRS vs COOK Comparison
Compare ACRS & COOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- COOK
- Stock Information
- Founded
- ACRS 2012
- COOK 1985
- Country
- ACRS United States
- COOK United States
- Employees
- ACRS N/A
- COOK N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- COOK Wholesale Distributors
- Sector
- ACRS Health Care
- COOK Consumer Discretionary
- Exchange
- ACRS Nasdaq
- COOK Nasdaq
- Market Cap
- ACRS 230.8M
- COOK 184.8M
- IPO Year
- ACRS 2015
- COOK 2021
- Fundamental
- Price
- ACRS $2.85
- COOK $0.84
- Analyst Decision
- ACRS Strong Buy
- COOK Hold
- Analyst Count
- ACRS 5
- COOK 7
- Target Price
- ACRS $9.75
- COOK $2.04
- AVG Volume (30 Days)
- ACRS 1.4M
- COOK 396.9K
- Earning Date
- ACRS 11-06-2025
- COOK 11-05-2025
- Dividend Yield
- ACRS N/A
- COOK N/A
- EPS Growth
- ACRS N/A
- COOK N/A
- EPS
- ACRS N/A
- COOK N/A
- Revenue
- ACRS $15,742,000.00
- COOK $582,799,000.00
- Revenue This Year
- ACRS N/A
- COOK N/A
- Revenue Next Year
- ACRS N/A
- COOK $2.21
- P/E Ratio
- ACRS N/A
- COOK N/A
- Revenue Growth
- ACRS N/A
- COOK N/A
- 52 Week Low
- ACRS $1.05
- COOK $0.75
- 52 Week High
- ACRS $4.24
- COOK $3.43
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- COOK 41.04
- Support Level
- ACRS $2.34
- COOK $0.77
- Resistance Level
- ACRS $2.57
- COOK $0.81
- Average True Range (ATR)
- ACRS 0.22
- COOK 0.07
- MACD
- ACRS 0.03
- COOK 0.00
- Stochastic Oscillator
- ACRS 96.18
- COOK 25.97
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About COOK Traeger Inc.
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.